
With multiple oral JAK inhibitors approaching approval, sequencing decisions and adverse-event management are becoming urgent clinical questions. Dr. Desai and Dr. Hamzavi outline how they select agents and manage risk.

With multiple oral JAK inhibitors approaching approval, sequencing decisions and adverse-event management are becoming urgent clinical questions. Dr. Desai and Dr. Hamzavi outline how they select agents and manage risk.

Patients rank stabilization above repigmentation, and the timeline for meaningful improvement can stretch to three years. Dr. Hamzavi lays out the goals and realistic expectations that should guide systemic therapy.

Curing vitiligo isn't currently possible, and Dr. Desai says saying so plainly builds trust. He explains how he sets realistic, patient-specific goals around activity control and repigmentation.

Ultra-potent topical steroids remain effective for vitiligo, but not without cost. Dr. Hamzavi weighs atrophy, systemic hormonal effects, and paradoxical hypopigmentation against the benefits of faster repigmentation.

Topical JAK inhibitors, phototherapy, and combination strategies now anchor first-line vitiligo treatment. Drs. Desai and Hamzavi compare their approaches and the evidence shaping how aggressively they treat localized disease.

Vitiligo care rarely stays within dermatology alone. The panel discusses when to loop in primary care, endocrinology, psychology, and patient support networks to address the disease's full burden.

Three subtle physical findings can signal that vitiligo is about to spread. Dr. Hamzavi outlines the warning signs of active disease and the practical scoring approach he uses instead of research metrics.

A careful physical exam, targeted laboratory testing, and a low threshold for biopsy remain the foundation of vitiligo diagnosis. Dr. Desai details the workup he uses with every new patient.

Vitiligo begins with oxidative stress and ends with CD8-positive T cells destroying melanocytes that cannot easily regenerate. Dr. Hamzavi maps the autoimmune cascade and the disease associations clinicians should watch for.

Vitiligo affects up to two percent of the population worldwide, yet payers and patients alike still misread it as cosmetic. Dr. Desai explains the autoimmune biology, systemic comorbidities, and diagnostic pitfalls that argue otherwise.

Iltefat Hamzavi, MD, discusses the importance of support groups and other helpful resources for families and caregivers of patients with hidradenitis suppurativa and provides closing thoughts for clinical providers.

Dr Hamzavi discusses how clinicians can address the psychosocial impact of hidradenitis suppurativa on patients and the rate of hospitalization.

Iltefat Hamzavi, MD, outlines comorbidities associated with hidradenitis suppurativa and discusses best practices for coordinating care between specialists.

An expert on hidradenitis suppurativa describes the characteristics for each of the 3 stages in the Hurley staging system and how they inform treatment decisions.

A dermatologist provides clinical insights on differential diagnosis strategies when considering hidradenitis suppurativa in patients and the challenges associated with diagnosis.

Iltefat Hamzavi, MD, describes the pathophysiology of hidradenitis suppurativa and associated comorbidities that are commonly seen in patients.

An expert on hidradenitis suppurativa discusses the epidemiology of the disease and its profound impact on patients’ lives.

Iltefat Hamzavi, MD, introduces a discussion on the treatment of hidradenitis suppurativa with an overview of the signs and symptoms of the disease.